ANRO Strangle Strategy
ANRO (Alto Neuroscience, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NYSE.
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects.
ANRO (Alto Neuroscience, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $948.9M, a beta of 1.25 versus the broader market, a 52-week range of 2.15-28.441, average daily share volume of 343K, a public-listing history dating back to 2024, approximately 76 full-time employees. These structural characteristics shape how ANRO stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.25 places ANRO roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a strangle on ANRO?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current ANRO snapshot
As of June 29, 2026, spot at $27.73, ATM IV 105.10%, IV rank 14.87%, expected move 30.13%. The strangle on ANRO below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 18-day expiry.
Why this strangle structure on ANRO specifically: ANRO IV at 105.10% is on the cheap side of its 1-year range, which favors premium-buying structures like a ANRO strangle, with a market-implied 1-standard-deviation move of approximately 30.13% (roughly $8.36 on the underlying). The 18-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ANRO expiries trade a higher absolute premium for lower per-day decay. Position sizing on ANRO should anchor to the underlying notional of $27.73 per share and to the trader's directional view on ANRO stock.
ANRO strangle setup
The ANRO strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ANRO near $27.73, the first option leg uses a $29.12 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ANRO chain at a 18-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ANRO shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $29.12 | N/A |
| Buy 1 | Put | $26.34 | N/A |
ANRO strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
ANRO strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on ANRO. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on ANRO
Strangles on ANRO are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ANRO chain.
ANRO thesis for this strangle
The market-implied 1-standard-deviation range for ANRO extends from approximately $19.37 on the downside to $36.09 on the upside. A ANRO long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current ANRO IV rank near 14.87% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ANRO at 105.10%. As a Healthcare name, ANRO options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ANRO-specific events.
ANRO strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ANRO positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ANRO alongside the broader basket even when ANRO-specific fundamentals are unchanged. Always rebuild the position from current ANRO chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on ANRO?
- A strangle on ANRO is the strangle strategy applied to ANRO (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With ANRO stock trading near $27.73, the strikes shown on this page are snapped to the nearest listed ANRO chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are ANRO strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the ANRO strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 105.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ANRO strangle?
- The breakeven for the ANRO strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ANRO market-implied 1-standard-deviation expected move is approximately 30.13%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on ANRO?
- Strangles on ANRO are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ANRO chain.
- How does current ANRO implied volatility affect this strangle?
- ANRO ATM IV is at 105.10% with IV rank near 14.87%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.